The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A multicenter, open, randomized, phase II study to investigate the sequential administration of docetaxel and intermittent erlotinib versus erlotinib as a second-line therapy for advanced non-small cell lung cancer (NSCLC).
F. Aparisi
No relevant relationships to disclose
J. Garcia Sanchez
No relevant relationships to disclose
A. Sanchez-Hernandez
No relevant relationships to disclose
V. Giner
No relevant relationships to disclose
J. Muñoz-Langa
No relevant relationships to disclose
G. Esquerdo
No relevant relationships to disclose
A. López Jiménez
No relevant relationships to disclose
J. Garde
No relevant relationships to disclose
O. Juan Vidal
No relevant relationships to disclose